%0 Journal Article
%A Escobar-Lopez, Luis
%A Ochoa, Juan Pablo
%A Mirelis, Jesus G.
%A Espinosa, Maria Angeles
%A Navarro, Marina
%A Gallego-Delgado, Maria
%A Barriales-Villa, Roberto
%A Robles-Mezcua, Ainhoa
%A Basurte-Elorz, Maria Teresa
%A Garcia-Moreno, Laura Gutierrez
%A Climent, Vicente
%A Jimenez-Jaimez, Juan
%A Mogollon-Jimenez, Maria Victoria
%A Lopez, Javier
%A Pena-Pena, Maria Luisa
%A Garcia-Alvarez, Ana
%A Brion, Maria
%A Ripoll-Vera, Tomas
%A Palomino-Doza, Julian
%A Tiron, Coloma
%A Idiazabal, Uxua
%A Brogger, Maria Noel
%A Garcia-Hernandez, Soledad
%A Restrepo-Cordoba, Maria Alejandra
%A Gonzalez-Lopez, Esther
%A Mendez, Irene
%A Sabater, Maria
%A Villacorta, Eduardo
%A Larranaga-Moreira, Jose M.
%A Abecia, Ana
%A Fernandez, Ana Isabel
%A Garcia-Pinilla, Jose M.
%A Rodriguez-Palomares, Jose F.
%A Gimeno-Blanes, Juan Ramon
%A Bayes-Genis, Antoni
%A Lara-Pezzi, Enrique
%A Dominguez, Fernando
%A Garcia-Pavia, Pablo
%T Association of Genetic Variants With Outcomes in Patients With Nonischemic Dilated Cardiomyopathy
%D 2021
%@ 0735-1097
%U https://hdl.handle.net/10668/26487
%X BACKGROUND The clinical relevance of genetic variants in nonischemic dilated cardiomyopathy (DCM) is unsettled. OBJECTIVES The study sought to assess the prognostic impact of disease-causing genetic variants in DCM. METHODS Baseline and longitudinal clinical data from 1,005 genotyped DCM probands were retrospectively collected at 20 centers. A total of 372 (37%) patients had pathogenic or likely pathogenic variants (genotype positive) and 633 (63%) were genotype negative. The primary endpoint was a composite of major adverse cardiovascular events. Secondary endpoints were end-stage heart failure (ESHF), malignant ventricular arrhythmia (MVA), and left ventricular reverse remodeling (LVRR) RESULTS After a median follow-up of 4.04 years (interquartile range: 1.70-7.50 years), the primary endpoint had occurred in 118 (31.7%) patients in the genotype-positive group and in 125 (19.8%) patients in the genotype-negative group (hazard ratio [HR]: 1.51; 95% confidence interval [CI]: 1.17-1.94; P = 0.001). ESHF occurred in 60 (16.1%) genotype-positive patients and in 55 (8.7%) genotype-negative patients (HR: 1.67; 95% CI: 1.16-2.41; P = 0.006). MVA occurred in 73 (19.6%) genotype-positive patients and in 77 (12.2%) genotype-negative patients (HR: 1.50; 95% CI: 1.092.07; P = 0.013). LVRR occurred in 39.6% in the genotype-positive group and in 46.2% in the genotype-negative group (P = 0.047). Among individuals with baseline left ventricular ejection fraction #35%, genotype-positive patients exhibited more major adverse cardiovascular events, ESHF, and MVA than their genotype-negative peers (all P
%K dilated cardiomyopathy
%K genetics
%K heart failure
%K left ventricular reverse remodeling
%K mutation
%K prognosis
%K sudden cardiac death
%K ventricular arrhythmia
%K Risk
%K Defibrillator
%K Guidelines
%K Management
%K Statement
%~